XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 6 Months Ended
Sep. 30, 2019
USD ($)
performance_obligation
material_right
Apr. 30, 2018
USD ($)
milestone
option
Jun. 30, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Accounts receivable     $ 2,716 $ 3,678
Kite Pharma, Inc.        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Increase in revenue     8,900  
Increased net income     $ 8,900  
Increased earnings per share, basic (in dollars per share) | $ / shares     $ 0.06  
Increased earnings per share, diluted (in dollars per share) | $ / shares     $ 0.06  
Kite Pharma, Inc. | License and Service        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Contract with customer liability   $ 150,000    
Number of remaining performance obligations | performance_obligation 4      
Number of material rights for renewal of research period | material_right 2      
Renewal period 1 year      
Fixed consideration $ 150,000      
Remaining performance obligation amount     $ 7,400 21,200
Remaining performance obligation amount, related to material rights     $ 1,500 $ 1,500
Kite Pharma, Inc. | License and Service | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Remaining performance obligation, expected timing of satisfaction period       12 months
Kite Pharma, Inc. | License and Service | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Remaining performance obligation, expected timing of satisfaction period     12 months  
Kite Pharma, Inc. | Collaboration And License Agreement        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Milestone payments received   $ 150,000    
Initial research term of agreement   6 years    
Number of options to extend initial research term | option   2    
Extended research term of agreement   1 year    
Separate fee for additional term   $ 10,000    
Contract with customer liability     $ 6,900 $ 19,400
Accounts receivable     $ 200 $ 700
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Contingent development and sales-based milestone payments to be received   1,300,000    
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Contingent development and sales-based milestone payments to be received   $ 1,800,000    
Maximum amount of achieved milestones to receive payment | milestone   10    
Kite Pharma, Inc. | Collaboration And License Agreement | Maximum        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Development and sales-based milestone payments to be received   $ 3,000,000